Lilly Endowment Amends Eli Lilly Stake, Passive Ownership Confirmed

TL;DR

**Lilly Endowment still holds Eli Lilly stock, no activist moves planned.**

AI Summary

Lilly Endowment Inc. filed an amended SC 13G/A on January 26, 2024, reporting its ownership of Eli Lilly and Company common stock as of December 31, 2023. This filing, Amendment No. 39, indicates a passive ownership stake, meaning the Endowment does not intend to influence or control Eli Lilly's management. For investors, this filing confirms a significant, long-term institutional holder maintains its position, which can be seen as a vote of confidence in Eli Lilly's stability and future prospects.

Why It Matters

This filing confirms that a major, long-standing shareholder, Lilly Endowment Inc., continues to hold a significant, passive stake in Eli Lilly and Company, signaling stability and a lack of immediate activist pressure.

Risk Assessment

Risk Level: low — The filing indicates a passive ownership stake, suggesting no immediate risk of disruptive shareholder activism or significant changes in company control.

Analyst Insight

Investors should note the continued passive ownership by Lilly Endowment Inc., which suggests long-term stability in the shareholder base and no immediate signs of activist intervention, allowing focus on Eli Lilly's operational performance.

Key Players & Entities

• Lilly Endowment Inc. (company) — the reporting person and a significant shareholder of Eli Lilly and Company
• Eli Lilly and Company (company) — the issuer whose common stock is being reported
• 03 Life Sciences (company) — an organization name associated with the subject company, Eli Lilly & Co.

FAQ

From the Filing

0000897101-24-000026.txt : 20240126 0000897101-24-000026.hdr.sgml : 20240126 20240126162545 ACCESSION NUMBER: 0000897101-24-000026 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240126 DATE AS OF CHANGE: 20240126 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ELI LILLY & Co CENTRAL INDEX KEY: 0000059478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 350470950 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-17885 FILM NUMBER: 24568261 BUSINESS ADDRESS: STREET 1: LILLY CORPORATE CTR STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 BUSINESS PHONE: 3172762000 MAIL ADDRESS: STREET 1: LILLY CORPORATE CENTER STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 FORMER COMPANY: FORMER CONFORMED NAME: LILLY ELI & CO DATE OF NAME CHANGE: 19941024 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: LILLY ENDOWMENT INC CENTRAL INDEX KEY: 0000316011 ORGANIZATION NAME: IRS NUMBER: 350868122 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 2801 NORTH MERIDIAN STREET CITY: INDIANANAPOLIS STATE: IN ZIP: 46208 BUSINESS PHONE: 3179245471 MAIL ADDRESS: STREET 1: 2801 NORTH MERIDIAN ST CITY: INDIANAPOLIS STATE: IN ZIP: 46208 SC 13G/A 1 lilly240086_sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 39) Eli Lilly and Company (Name of Issuer) Common Stock, Without Par Value (Title of Class of Securities) 532457-10-8 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: o Rule 13d-1(b) o Rule 13d-1(c) ü Rule 13d-1(d) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. 1 of 5 CUSIP No. 532457-10-8 	13G 1 NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY). LILLY ENDOWMENT INC. 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) ¨ This filing describes the reporting person’s relationship with other persons, but the reporting person does not affirm the existence of a group. 	 (b) ¨ 3 SEC USE ONLY 4 CITIZENSHIP OR PLACE OF ORGANIZATION INDIANA NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5 SOLE VOTING POWER 99,768,810 6 SHARED VOTING POWER 0 7 SOLE DISPOSITIVE POWER 99,768,810 8 SHARED DISPOSITIVE POWER 0 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 99,768,810 10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES Not applicable 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.51% 12 TYPE OF REPORTING PERSON CO FOOTNOTES: The percent of class represented is based on 949,307,237 shares of common stock outstanding as of October 30, 2023, as reported on the Issuer’s Form 10Q for the period ended September 30, 2023. 2 of 5 Item 1. (a) Name of Issuer Eli Lilly and Company (b) Address of Issuer's Principal Executive Offices Lilly Corporate Center, Indianapolis, Indiana 46285 Item 2. (a) Name of Per